Moderna
- Market cap
- 78.44B
- P/E (TTM)i
- -24.62
- P/Bi
- 11.60
- EPSi
- -7.26
- Div yieldi
- 0.00%
- 52W posi
- 92%
Anonymous reader poll. Unscientific, not investment advice.
Moderna ended the session at 196.48, up 4.81%. Its market capitalisation is about 78.44B, the #406 most valuable US-listed company we track. Valuation-wise, the P/E sits at -25.46, 2184% below the five-year average of 1.22. Wall Street's 13-analyst consensus lands on Hold, with a price target averaging 117.44 (-40% from here). Against a 52-week band of 22.28-212.22, the shares are currently 92% of the way up.
✦ StockVane Quant Insights how this is computed
- In the model portfolio — top-12 twelve-month momentum, trading above its 200-day average.
- Signal has read STRONG BUY for 1 month.
- Recent price momentum is +382.5% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 8.2% of float.
- Analyst tilt is Hold.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 54.8% | Better than 68% |
| Operating margin | -159.9% | Better than 2% |
| Net margin | -146.8% | Better than 2% |
| Return on equity | -28.9% | Better than 4% |
| Return on invested capital | -28.3% | Better than 4% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 154.7% | Better than 100% |
| 6-month return | 305.5% | Better than 100% |
| 12-month return (ex latest month) | 428.5% | Better than 100% |
| Distance below 52-week high | 2.7% | Better than 95% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.3x | Better than 84% |
| Debt to assets | 15.1% | Better than 71% |
| Interest coverage | -275.8x | Better than 1% |
| Free cash flow / net income | 54.8% | Better than 14% |
Analyst View F
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 23.1% | Better than 9% |
| Upside to average target | -42.2% | Better than 0% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 187.46
- Open
- 183.65
- Day range
- 182.50 - 197.69
- Avg price
- 192.38
- Volume
- 14.64M
- Turnover
- 2.82B
- Turnover ratei
- 3.93%
- Volume ratioi
- 0.86
- Amplitudei
- 8.10%
- 52-week rangei
- 22.28 - 212.22
Valuation
- P/Ei
- -27.06
- P/E (TTM)i
- -24.62
- P/Bi
- 11.60
- EPSi
- -7.26
- Book value / shi
- 16.94
- Net profit
- -2.90B
- Net assets
- 6.76B
Share structure
- Market cap
- 78.44B
- Float capi
- 73.14B
- Shares out
- 399.24M
- Float sharesi
- 372.26M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-12-07
7.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+290.91M net over the window
Short interest
- Shares short
- 32.87M
- % of floati
- 8.23%
- Days to coveri
- 2.53
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Moderna (MRNA)?
Moderna last traded at 196.48. The quote on this page refreshes every few seconds while US markets are open.
What is Moderna's market cap?
About 78.44B.
What is the P/E ratio of Moderna?
The trailing twelve-month P/E is -24.62, below its own 5-year average of 1.22 — toward the bottom of its historical range (0.16% percentile). See the Valuation tab for the full history.
Does Moderna pay a dividend?
Moderna does not currently pay a regular dividend.
Is Moderna a buy according to analysts?
The consensus of 13 analysts is a Hold rating, with an average 12-month price target of 117.44, which implies 40.2% downside from the current price. This is not investment advice.
What is Moderna's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Moderna a A (Strong Buy). In the model portfolio — top-12 twelve-month momentum, trading above its 200-day average. Not investment advice.
Quote time 2026-10-08 08:19:58 · For reference only, not investment advice and not tailored to your situation.